Pomalidomide therapy for multiple myeloma and myelofibrosis: an update.
about
Immunomodulatory agents in myelofibrosis.Sensitive liquid chromatography/mass spectrometry methods for quantification of pomalidomide in mouse plasma and brain tissueMolecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma.Immunotherapy Strategies Against Multiple Myeloma.
P2860
Pomalidomide therapy for multiple myeloma and myelofibrosis: an update.
description
2011 nî lūn-bûn
@nan
2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Pomalidomide therapy for multiple myeloma and myelofibrosis: an update.
@ast
Pomalidomide therapy for multiple myeloma and myelofibrosis: an update.
@en
Pomalidomide therapy for multiple myeloma and myelofibrosis: an update.
@nl
type
label
Pomalidomide therapy for multiple myeloma and myelofibrosis: an update.
@ast
Pomalidomide therapy for multiple myeloma and myelofibrosis: an update.
@en
Pomalidomide therapy for multiple myeloma and myelofibrosis: an update.
@nl
prefLabel
Pomalidomide therapy for multiple myeloma and myelofibrosis: an update.
@ast
Pomalidomide therapy for multiple myeloma and myelofibrosis: an update.
@en
Pomalidomide therapy for multiple myeloma and myelofibrosis: an update.
@nl
P2860
P1433
P1476
Pomalidomide therapy for multiple myeloma and myelofibrosis: an update.
@en
P2860
P304
P356
10.3109/10428194.2011.552139
P577
2011-02-21T00:00:00Z